Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

17.53USD
21 Sep 2018
Change (% chg)

$-0.10 (-0.57%)
Prev Close
$17.63
Open
$17.62
Day's High
$17.86
Day's Low
$17.35
Volume
652,382
Avg. Vol
457,133
52-wk High
$20.85
52-wk Low
$1.36

Summary

Name Age Since Current Position

John Aplin

72 2011 Independent Chairman of the Board

Michael Sherman

51 2017 President, Chief Executive Officer, Director

Michael Andriole

45 2017 Chief Financial Officer

Beth Taylor

52 2016 Chief Accounting Officer, Vice President - Finance

Philip Low

70 1998 Chief Science Officer, Director

Erik Chelius

55 2018 Vice President - CMC

Christopher Leamon

51 2000 Vice President - Research

P. David Mozley

2015 Vice President - Imaging

Katherine K. Parker

53 2015 Vice President - Human Resources

Alison Armour

54 2015 Chief Medical Officer

Colin Goddard

58 2013 Independent Director

Marc Kozin

56 2012 Independent Director

Patrick Machado

54 2018 Independent Director

Fred Middleton

68 2001 Independent Director

Lesley Russell

57 2017 Independent Director

Biographies

Name Description

John Aplin

Dr. John C. Aplin, Ph.D., is an Independent Chairman of the Board of Endocyte, Inc. since May 2011. Dr. Aplin has served as a member of Board of Directors since May 2003 and as Chairman since May 2011. Since November 1990, Dr. Aplin has served as General Partner and Managing Director of CID Capital, a private equity firm. Dr. Aplin has served on the board of directors of 25 companies and was the Chairperson of the M.B.A. program at Indiana University. Dr. Aplin holds a B.S. in business administration from Drake University, and an M.A. and a Ph.D. in business administration from the University of Iowa. Dr. Aplin is also a Certified Management Consultant. We believe that Dr. Aplin possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his experience in the venture capital and private equity industries, his years of business and leadership experience and his financial sophistication and expertise.

Michael Sherman

Mr. Michael A. Sherman is the President, Chief Executive Officer, Director of Endocyte, Inc. Mr. Sherman was Chief Financial Officer, Chief Operating Officer of Endocyte, Inc. Mr. Sherman has served as the Company’s Chief Financial Officer since October 2006. From December 1994 to October 2006, Mr. Sherman served in various executive roles, but most recently as Vice President of Finance and Strategic Planning from May 2004 to October 2006, of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Sherman serves on the Board of Directors of Mead Johnson Nutrition Company, a pediatric nutrition company. Mr. Sherman also serves on the Indianapolis Children’s Museum Board of Trustees. Mr. Sherman holds a B.A. in economics from DePauw University and an M.B.A. from the Amos Tuck School, Dartmouth College. We believe that Mr. Sherman possesses specific attributes that qualify him to serve as a member of our Board of Directors, including the perspective and experience he brings as our President and Chief Executive Officer. Mr. Sherman was previously our Chief Financial Officer and Chief Operating Officer and has over 10 years of historic knowledge and operational expertise with our company.

Michael Andriole

Mr. Michael T. Andriole is the Chief Financial Officer of Endocyte, Inc. Mr. Andriole, served in various executive roles at Eli Lilly and Company, a large pharmaceutical company that develops, manufactures and markets pharmaceutical products on a global basis, from June 2001 to February 2017. He most recently served as Vice President, Corporate Business Development of Eli Lilly and Company from June 2011 to February 2017. Other positions that Mr. Andriole held at Eli Lilly and Company included Director, European Development and Strategic Planning in London, England and Director, Corporate Finance and Investment Banking. Mr. Andriole graduated cum laude from Xavier University’s Williams College of Business and holds a B.S. in Finance and an M.B.A. from Kelley School of Business, Indiana University.

Beth Taylor

Ms. Beth A. Taylor is the Vice President of Finance and Chief Accounting Officer of Endocyte, Inc. Ms. Taylor is the Corporate Controller of Endocyte, Inc. Ms. Taylor has served as our Corporate Controller since January 2011. Ms. Taylor has served as Corporate Controller since January 2011. Ms. Taylor served as Corporate Controller of Author Solutions, Inc. from December 2009 to December 2010, as Vice President of Accounting, Financial Reporting and Control at Harlan Laboratories, Inc. from July 2007 to May 2009 and in various roles at Republic Airways Holdings, Inc. from May 1999 through June 2007, including Vice President and Corporate Controller from August 2004 through June 2007. Ms. Taylor holds a B.S. in Accounting from Kelley School of Business, Indiana University.

Philip Low

Dr. Philip S. Low, Ph.D., is the Chief Science Officer, Director of Endocyte, Inc. Dr. Low is one of the founders and has served as our Chief Science Officer since April 1998 and as a member of our Board of Directors since December 1995. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Director of the Purdue Center for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low holds a B.S. in chemistry from Brigham Young University and a Ph.D. in biochemistry from the University of California, San Diego. We believe that Dr. Low possesses specific attributes that qualify him to serve as a member of our Board of Directors, including the perspective and experience he brings as our Chief Science Officer and as one of our co- founders, which brings historic knowledge, scientific expertise and continuity to our Board of Directors.

Erik Chelius

Dr. Erik C. Chelius is the Vice President - CMC of Endocyte, Inc, since January 2018. Dr. Chelius previously served as our Senior Director of CMC from September 2014 until January 2018 and as a Senior Research Scientist for us from 2011 to 2014. Prior to joining us, Dr. Chelius worked in the Development and Manufacturing departments of Eli Lilly & Co. from 1989 through 2010. He also has contract manufacturing experience gained while employed at Evonik from 2010 through 2011. Dr. Chelius holds a B.S. in Chemistry from Marquette University as well as M.S. and Ph.D. degrees in Chemistry from Northwestern University.

Christopher Leamon

Dr. Christopher P. Leamon, Ph.D., is the Vice President - Research of Endocyte, Inc. From February 1999 to April 2000, Dr. Leamon has served as our Vice President of Research since April 2000. From February 1999 to April 2000, Dr. Leamon served as our Director of Biology and Biochemistry. Prior to joining us, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome and DNA drug delivery for GlaxoWellcome, a healthcare company and Isis Pharmaceuticals, a biomedical pharmaceutical company. Dr. Leamon holds a B.S. in chemistry from Baldwin Wallace College and a Ph.D. in biochemistry from Purdue University.

P. David Mozley

Dr. P. David Mozley, M.D. is no longer the Vice President - Imaging of Endocyte, Inc. Dr. Mozley will provide medical and scientific leadership across Endocyte's companion imaging agent portfolio. Dr. Mozley has over 25 years of experience using radiopharmaceuticals to diagnose and treat diseases. He is a board-certified physician in nuclear medicine. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan. From 2001 to 2012, Dr. Mozley held multiple positions with progressively increasing responsibilities at Eli Lilly and Merck & Co. While at Merck & Co., he served as senior imaging lead across therapeutic areas for multi-center trials that used imaging as a major endpoint, chaired the PhRMA Imaging group, and co-chaired a technical committee on quantitative imaging for the Radiological Society of North America. He has contributed to the publication of over 100 research reports in the literature on imaging. Dr. Mozley received his B.S. at the College of William & Mary, Williamsburg, VA, his M.D. from the Brody School of Medicine at East Carolina University, and trained at the University of Pennsylvania in Philadelphia.

Katherine K. Parker

Ms. Katherine K. Parker is the Vice President of Human Resources of Endocyte, Inc, since January 2015. From December 2013 to January 2015, she has served as Vice President of Human Resources since January 2015. From December 2013 to January 2015, she served as our Senior Director of Human Resources. Prior to December 2013, Ms. Parker served as Principal for Auxilius International, LLC from August 2010 to December 2013. She also has served as President/Owner of Auxilius Heavy Industries, LLC, a wind turbine maintenance, cleaning and repair company, from August 9, 2013 to the present. Prior to her entrepreneurial endeavors, Ms. Parker worked at Hyundai Motor America for 21 years, most recently as Vice President of Human Resources and Administrative Services from April 2005 to April 2009. Ms. Parker holds a B.A. in history from the University of California, Los Angeles and an M.B.A. from California State University, Dominguez Hills.

Alison Armour

Dr. Alison A. Armour, M.D. is the Chief Medical Officer of Endocyte, Inc, since August 2015. Prior to joining us, Dr. Armour served as Vice President of Oncology and led the Tykerb, a breast cancer drug, program at GlaxoSmithKline PLC and Novartis AG from August 2011 to July 2015. From August 2004 to August 2011 she was Global Medical Science Director at AstraZeneca PLC. Before joining the pharmaceutical industry, Dr. Armour established herself as a thought leader in medical and radiation oncology. Dr. Armour holds her B.Sc. in Biochemistry, M.B., Ch.B., MSc., and Doctorate of Medicine from the University of Glasgow, MRCP from the Member of the Royal College of Physicians Glasgow, and her FRCR from the Royal College of Radiologists London, UK.

Colin Goddard

Dr. Colin Goddard, Ph.D., is an Independent Director of Endocyte Inc. Dr. Goddard has served as a member of Board of Directors since November 2013. Dr. Goddard has served as Chairman and Chief Executive Officer of Coferon, Inc., a private biotechnology platform company, since April 2011. From October 1998, until its acquisition by Astellas Pharmaceuticals, Inc. in July 2010, Dr. Goddard served as Chief Executive Officer of OSI Pharmaceuticals, Inc., or OSI, and member of its Board of Directors. Dr. Goddard joined OSI as a scientist in 1989 and held positions that included Director of Drug Discovery, Chief Operating Officer and President. Dr. Goddard also chaired the OSI board from 2000 – 2002. Prior to his employment at OSI, Dr. Goddard was a research fellow at the National Cancer Institute in Bethesda, MD. Dr. Goddard also chairs the board of Merganser Biotech and serves on the boards of PanOptica, Inc. and Agendia NV, all private biotech companies. Dr. Goddard received his Ph.D. in Cancer Pharmacology from the University of Aston in Birmingham, U.K. and a B.Sc (Hons) in Biochemistry from the University of York, U.K. We believe that Dr. Goddard possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his years of experience in the biotechnology, diagnostic and related industries, and his scientific background and industry knowledge.

Marc Kozin

Mr. Marc D.Kozin is an Independent Director of Endocyte, Inc., effective July 25, 2012. Mr. Kozin has served as a member of Board of Directors since July 2012. Mr. Kozin has been a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, since July 2011. Prior to that, Mr. Kozin served as president of L.E.K.’s North American practice for 15 years. Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. Mr. Kozin serves as a member of the board of directors, and as the chairman of the audit committee, of Flex Pharma, Inc., a biopharmaceutical company, and he also serves as a member of the board of directors of UFP Technologies, Inc., a designer and manufacturer of engineered packaging solutions and engineered component products, DYAX Corp., a biopharmaceutical company, OvaScience, Inc., a global life science company, and two privately-held companies. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania. We believe that Mr. Kozin possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally, as well as his deep industry expertise advising biopharmaceutical, life sciences and medical technology companies.

Patrick Machado

Mr. Patrick Machado is an Independent Director of Endocyte, Inc. Mr. Machado is a seasoned biotech executive and experienced board member with more than 20 years of experience leading finance, business development, and legal functions. In addition to being a qualified financial and legal expert, he has a broad business background. Most recently, he was a co-founder, Chief Business Officer and Chief Financial Officer of Medivation, Inc., providing strong leadership in the development of XTANDI® and its successful commercial launch in prostate cancer. Mr. Machado served as a member of its Board of Directors until its acquisition by Pfizer in 2016. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc. as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. Mr. Machado also serves as a member of the Board of Directors of public pharmaceutical companies Chimerix, Inc., Scynexis, Inc., and Adverum Biotechnologies, Inc. We believe that Mr. Machado possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his years of experience in the biotechnology industry, and his financial, business development, and legal expertise.

Fred Middleton

Mr. Fred A. Middleton is an Independent Director of Endocyte, Inc., since July 2001. Mr. Middleton has served as a member of Board of Directors since July 2001. Since 1987, Mr. Middleton has been a General Partner and Managing Director of Sanderling Ventures, a biomedical venture capital firm. During the last 30 years, Mr. Middleton has served in a number of roles as a member of management, board member or an investor in over 25 biomedical companies. Mr. Middleton currently serves as a director of Stereotaxis, Inc. (STXS), a medical device company. During the past five years, he was also a member of board of directors of CardioNet, Inc. (BEAT), a cardiac rhythm management services company, and Pacira Pharmaceuticals, Inc. (PCRX), a therapeutic drug company. Mr. Middleton also serves on the board of directors of several privately-held biomedical and biotechnology companies. Mr. Middleton holds a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. with distinction from the Harvard Business School. We believe that Mr. Middleton possesses specific attributes that qualify him to serve as a member of the Board of Directors, including his experience in the venture capital industry and his general operational and management experience working with early-stage biomedical companies.

Lesley Russell

Dr. Lesley Russell, M.B.Ch.B., is an Independent Director of Endocyte, Inc. Dr. Russell is the Director of Endocyte, Inc., effective January 8, 2013. Dr. Russell has served as a member of Board of Directors since January 2013. Dr. Russell has served as the Chief Operating Officer of TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, since August 2013. Prior to that position, Dr. Russell served as senior vice president and head of research and development for global branded products at Teva Pharmaceutical Industries Limited, a global pharmaceutical company, from October 2011 until June 2012. Prior to that position, she was executive vice president and chief medical officer at Cephalon, Inc., a global biopharmaceutical company. Dr. Russell joined Cephalon in 2000 and held various positions of increasing responsibility, including head of clinical research and medical affairs, prior to becoming Cephalon’s chief medical officer in September 2006. Before joining Cephalon, Dr. Russell held positions of increasing responsibility at Amgen U.K., Lilly Industries Ltd., U.K., and U.S. Bioscience, now acquired by MedImmune Oncology. Dr. Russell currently serves as a member of the board of directors of AMAG Pharmaceuticals, Inc. (AMAG), a biopharmaceutical company. Dr. Russell holds a M.B.Ch.B. degree from the University of Edinburgh, Scotland. Dr. Russell is a member of the Royal College of Physicians, UK, and is registered with the General Medical Council, UK. Dr. Russell currently serves as a member of the board of directors of AMAG Pharmaceuticals and ENANTA Pharmaceuticals, both traded on Nasdaq. We believe that Dr. Russell possesses specific attributes that qualify her to serve as a member of our Board of Directors, including her experience in advancing products through late-stage clinical development and in navigating the new drug approval process at the FDA.

Basic Compensation